MGH treatment for Extravasation-Induced Injuries in Preterm Neonates
Can Medical Grade Honey heal extravasation wounds in preterm neonatal patients?
We are proud to present to you the latest L-Mesitran PubMed indexed publication. In this fourth (!) publication of Smaropoulos and Cremers, they present a case series of Preterm Neonates with extravasation injuries treated with L-Mesitran Ointment. A brief summary of the article can be found here.
In the current publication, seven cases of extravasation-induced injuries in preterm neonatal patients treated with L-Mesitran will be presented. The median gestational age was 32 weeks and the median weight was 1440g,
and all extravasation-induced injuries occurred on the extremity in which a PIV line was placed.
After L-Mesitran treatment, all extravasation wounds presented with granulation tissue formation progressed to normal epithelialization and closed in 7 to 67 days (median: 32 days). Upon initial application, peripheral edema and inflammation decreased. When present, necrotic tissue was effectively debrided, slough was removed, and no signs of infection were detected, irrespective of initial wound presentations. Cicatrization was minimal, and the full range of motion was preserved in all cases. L-Mesitran’s Medical Grade Honey (MGH) possesses antimicrobial, anti-inflammatory, and antioxidative activity, enhancing wound healing.
In all seven cases presented, MGH was safe and effective in the variety of location and extent of injuries experienced. No signs of pain or adverse events were observed. Based on these results obtained in extravasation injuries in preterm neonates, we recommend the use of MGH for extravasation-caused wounds and consideration of MGH for other types of wounds.
Are you interested in reading the full article? Contact us here.